59f108c6-677f-4cf2-89fd-6bd15133dd6f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.530
- ALLOGRAFT_REJECTION+0.470
- IL6_JAK_STAT3_SIGNALING+0.470
- HEDGEHOG_SIGNALING+0.420
- INTERFERON_GAMMA_RESPONSE+0.390
- MYOGENESIS+0.390
- INFLAMMATORY_RESPONSE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.350
- COMPLEMENT+0.340
Top 10 suppressed
- MYC_TARGETS_V2-0.780
- MYC_TARGETS_V1-0.740
- E2F_TARGETS-0.680
- OXIDATIVE_PHOSPHORYLATION-0.650
- G2M_CHECKPOINT-0.600
- MTORC1_SIGNALING-0.520
- DNA_REPAIR-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.440
- CHOLESTEROL_HOMEOSTASIS-0.360
- PEROXISOME-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.974 |
| 2 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.958 |
| 3 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.956 |
| 4 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.947 |
| 5 | SRR2771286 | — | — | 0.945 |
| 6 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.942 |
| 7 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.936 |
| 8 | 640b257c-bbc3-4483-a7b5-191bb7ef5421 | — | — | 0.933 |
| 9 | 40b98f15-43cb-426b-880c-951a4b28c3e2 | — | — | 0.932 |
| 10 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |